Evogene (EVGN) EBT Margin Growth (5y) (2017 - 2026)
Evogene (EVGN) EBT Margin Growth (5y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36,747.00 |
| Dec 31, 2025 | 78,946.00 |
| Sep 30, 2025 | 83,798.00 |
| Jun 30, 2025 | 121,735.00 |
| Mar 31, 2025 | 952,945.00 |
| Dec 31, 2024 | 581,244.00 |
| Sep 30, 2024 | 428,338.00 |
| Jun 30, 2024 | 140,385.00 |
| Mar 31, 2024 | 98,639.00 |
| Dec 31, 2023 | -35,149.00 |
| Sep 30, 2023 | 120,808.00 |
| Jun 30, 2023 | 6,880.00 |
| Mar 31, 2023 | 37,467.00 |
| Dec 31, 2022 | 27,584.00 |
| Sep 30, 2022 | -86,439.00 |
| Jun 30, 2022 | -271,173.00 |
| Mar 31, 2022 | -317,020.00 |
| Dec 31, 2021 | -203,959.00 |
| Sep 30, 2021 | -518,829.00 |
| Jun 30, 2021 | -486,056.00 |